Simnotrelvir

Cat. No.:	HY-154965		
CAS No.:	2920904-06-7		
Molecular Formula:	$C_{22}H_{30}F_3N_5O_4S_2$		
Molecular Weight:	549.63		
Target:	SARS-CoV		
Pathway:	Anti-infecti	on	
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (181.94 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.8194 mL	9.0970 mL	18.1941 mL		
		5 mM	0.3639 mL	1.8194 mL	3.6388 mL		
		10 mM	0.1819 mL	0.9097 mL	1.8194 mL		
	Please refer to the sol	lease refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (4.55 mM); Clear solution; Need ultrasonic						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.55 mM); Clear solution; Need ultrasonic						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (4.55 mM); Clear solution; Need ultrasonic						

BIOLOGICAL ACTIV	
Description	SARS-CoV-2-IN-41 (compound 2) is a potent SARS-CoV-2 3CL ^{pro} inhibitor with an IC ₅₀ value of 0.022 μM. SARS-CoV-2-IN-41 shows antiviral effect ^[1] .
IC ₅₀ & Target	IC ₅₀ : 0.022 μM (SARS-CoV-2 3CL ^{pro}) ^[1]
In Vivo	SARS-CoV-2-IN-41 (50, 200 mg/kg; I.p.) antiviral effect in SARS-CoV-2 infected mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Product Data Sheet

ŅΗ

HN,

0

Ο

0 ___N

0

Animal Model:	7-8 weeks, hACE2-K18 transgenic mice (infected with the delta strain of SARS-CoV-2 by intranasal drops) $^{\left[1 ight]}$
Dosage:	50, 200 mg/kg (combined with 50 mg/kg cytochrome P450 inhibitor ritonavir)
Administration:	I.p.; dose on day 0 1 time, 2 times on the 1st day, 1 time on the 2nd day
Result:	Significantly reduced the viral load in the lungs, after 4 days of infection, a sustained inhibitory effect of compound 2 on viral copy number was observed.

REFERENCES

[1]. XiangRui et al. Cyano compound, and preparation method therefor and use thereof. WO2023051657A1.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA